

UNIVERSITY OF BIRMINGHAM

Research at Birmingham

Comorbidities in Heart Failure

Hopper, Ingrid ; Kotecha, Dipak; Chin, Ken Lee ; Mentz, Robert ; von Lueder, Thomas

DOI:

[10.1007/s11897-016-0280-1](https://doi.org/10.1007/s11897-016-0280-1)

License:

None: All rights reserved

Document Version

Peer reviewed version

Citation for published version (Harvard):

Hopper, I, Kotecha, D, Chin, KL, Mentz, R & von Lueder, T 2016, 'Comorbidities in Heart Failure: Are There Gender Differences?', *Current heart failure reports*, vol. 13, no. 1, pp. 1-12. <https://doi.org/10.1007/s11897-016-0280-1>

[Link to publication on Research at Birmingham portal](#)

Publisher Rights Statement:

Eligibility for repository: Checked on 9/3/2016

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Comorbidities in Heart Failure: Are There Gender Differences?

Ingrid Hopper, MD^{1,2}; Dipak Kotecha, MD, PhD^{1,3}; Ken Lee Chin, MPharm^{1,2}; Robert J. Mentz, MD⁴; and Thomas G. von Lueder, MD, PhD^{1,5}

¹Monash Centre of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Alfred Hospital, Melbourne, Australia; ²Clinical Pharmacology Department, Alfred Health, Melbourne, Australia; ³University of Birmingham Centre for Cardiovascular Sciences, Medical School, Birmingham, UK; ⁴Duke University, Durham, North Carolina, USA, ⁵Department of Cardiology, Oslo University Hospital Ullevål, 0407 Oslo, Norway

Authors' email addresses:

Dr Ingrid Hopper: <ingrid.hopper@monash.edu>

Dr Dipak Kotecha: <d.kotecha@bham.ac.uk>

Mr. Ken Lee Chin: <ken.chin@monash.edu>

Dr. Robert Mentz: <robert.mentz@duke.edu>

Dr Thomas von Lueder: <tomvonoslo@yahoo.com>

Word count: 4,183 excluding references and table

Correspondence:

Dr. Thomas G. von Lueder, MD, PhD, FESC

Department of Cardiology

Oslo University Hospital

Post Box 4950 Nydalen

0424 Oslo, Norway

Fax +47 2211 9181

Phone +47 2211 9100

E-mail: <tomvonoslo@yahoo.com>

Abstract

Compared to men, women with heart failure (HF) are often older, smoke less, and have more preserved ejection fraction (EF), and hypertensive HF rather than HF of ischemic etiology. Gender-stratified outcome on comorbidities data in HF are scarce. Women have traditionally been under-represented in HF trials. Although data suggest that overall prognosis may be better in women, they experience lower quality of life with greater functional impairment from HF compared to men. Gender-differences have been reported for comorbid diabetes, chronic obstructive pulmonary disease, renal dysfunction, anemia and depression, and may explain gender disparity in outcomes. However, possible confounding of comorbidities with known prognostic determinants in HF (such as EF) as well as gender-differences in the utilization of medical therapies obscures interpretation.

In this review, we will explore the evidence for gender differences in non-cardiovascular comorbidities in HF. Our findings may guide clinicians to individualize HF care, according to best-practice, in the hope of improving prognosis for this chronic and debilitating condition.

Keywords

Comment [KHSSU1]: 6-8 keywords separated by semicolons

Introduction

The prevalence of heart failure (HF) is projected to increase substantially due to the ageing of populations and increased longevity¹. The majority of HF patients suffer from comorbidities, defined as cardiovascular and non-cardiovascular chronic conditions that co-exist with the primary illness of HF²⁻⁵. Comorbidities put an additional burden on patients, healthcare utilization and expenditure for HF, and are associated with worse outcome^{4, 6, 7}. Moreover, comorbidities may constitute risk factors for HF, trigger episodes of exacerbation, and have been proposed to drive the underlying disease process^{3, 8}. A recent study providing longitudinal follow-up data of community-dwelling HF patients suggests that the percentage of HF patients with 4 or more comorbidities has increased substantially in recent years⁹. Another contemporary report showed that non-cardiovascular comorbidities constitute a greater hazard for hospitalizations and death than cardiovascular diseases in this population¹⁰.

There is a paucity of gender-specific data on comorbidities in HF. Despite the fact that more than half of the patients with HF in routine care are women, randomized clinical trials (RCT) supporting current HF management guidelines have recruited predominantly male subjects with a lack of prospective gender-specific analyses. Some evidence, largely from registries, demonstrates important gender-differences in HF etiology, risk factors, and clinical presentation: Women, compared to men, tend to be older; with higher blood pressure and non-ischemic HF etiology, as well as more comorbidities such diabetes, renal disease and arthritis^{11, 12}. Accumulating evidence suggests better overall prognosis for women with HF compared to men, although it is not possible to entirely separate the impact of these differences according to comorbidity burden¹³⁻²³.

The Meta-Analysis Global Group In Chronic Heart Failure (MAGGIC), comprising individual patient data from 31 prospective observational and randomized studies in almost 42,000 patients with a mean follow-up of three years is currently the largest database containing gender-specific data in HF. MAGGIC demonstrated better survival for women irrespective of ejection fraction (EF) and age, although the gender-specific survival benefit was attenuated in subjects with ischemic etiology and those with comorbid diabetes^{9, 24}. Also, the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF) in HF outpatients with reduced ejection fraction showed that women were more likely to

have advanced CKD²⁵. In contrast, the multicenter Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF) registry involving 48,612 patients with HF showed a similar burden of comorbidity and outcomes for both genders¹⁷.

The evidence on gender-specific outcomes appears to be different between acute and chronic stable HF phenotypes. The Acute Decompensated Heart Failure National Registry (ADHERE) database and the American Heart Association Get With The Guidelines-Heart Failure (GWTG-HF) registry each comprising data from approximately 100,000 hospitalizations reported important gender differences for patient characteristics for the majority of comorbidities, but similar clinical outcomes for both genders^{26, 27}. Likewise, the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) Trial in 4,133 patients hospitalized for HF and EF of $\leq 40\%$ reported similar rates for all-cause mortality and CV death or HF hospitalizations for women and men²³.

Comorbidities burden in HF increase with age, may exacerbate the progression and clinical severity of HF, and possibly be of prognostic importance^{28, 29}. Several important differences between HF with reduced EF (HFrEF) compared to preserved EF (HFpEF; commonly defined as $EF \geq 40\%$, 45% or 50%) exist where diabetes, anemia, chronic obstructive pulmonary disease (COPD) and obesity were more commonly observed in patients with HFpEF^{4, 26, 30, 31}. In general, in women HFpEF is more predominant than HFrEF^{4, 10, 26, 27, 29, 32-34}. Comorbidities exacerbate morbidity and mortality in HF although close relationships with other well-established prognostic determinants such as EF likely contribute.

This manuscript discusses the available evidence from registries, administrative data from healthcare providers and clinical trials on gender-specific differences in major non-cardiovascular chronic conditions comorbid to HF.

Diabetes

Diabetes mellitus is not only a common and important comorbidity to HF, but also exerts maladaptive cardiovascular effects such as promoting coronary atherosclerosis, adverse myocardial remodelling, endothelial dysfunction, autonomic neuropathy, renal failure³⁵. Diabetes is typically defined by clinical history, although some studies have distinguished between diabetes subtypes and/or insulin dependency. The reported prevalence of diabetes in clinical trials in HF ranges

Comment [AC2]: Better: Comorbidity burden?

Comment [AC3]: better add \geq ?

Comment [AC4]:

between 11% and 50% (Table)^{4, 5, 23, 34, 36}{Ghali, 2001 #13769;Simon, 2001 #13770}.

Comment [AC5]: eliminate?

Data from large registries such as OPTIMIZE-HF, ADHERE and GWTG-HF suggest a higher prevalence of diabetes of 30% to 44% in real-world patients with HF^{17, 26, 31, 37}. The Framingham study reported a prevalence of 26% and 14% of women and men with HF, respectively^{5, 38}.

The overall prevalence of diabetes (i.e., including both type 1 and type 2) among the 2,400 women and 5,199 men randomized in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program was similar in women (30%) and in men (28%). No significant gender differences were found for type 2 diabetes (18% in women vs 20% in men; OR 0.95 (95% CI 0.84 to 1.08)) but significantly more women suffered from type 1 diabetes (12% vs men 8%; OR 1.52 (95% CI 1.29 to 1.79); $P < 0.001$)²².

Gender-stratified analysis of the Cardiac Insufficiency Bisoprolol Study (CIBIS-II) reported a fairly low prevalence of diabetes with no significant differences according to gender (women 14% versus men 11%, $P = 0.117$). Overall, women exhibited substantially lower rates of all-cause and cardiovascular mortality than men³⁹.

Among 5,491 patients hospitalized with new or worsening HF in relation to the Danish Investigations of Arrhythmia and Mortality on Dofetilide (DIAMOND) study, diabetes was present in 900 subjects (16%) of whom 370 were women and 530 men³³. The investigators showed that diabetes was independently associated with increased mortality in patients hospitalized with HF (RR: 1.5; 95% CI 1.4 to 1.6; $p < 0.0001$). Of note, diabetes was associated with a larger increase in mortality in women than in men (RR 1.7 (95% CI 1.4 to 1.9) vs RR 1.4 (1.3 to 1.6), $p < 0.0001$).

In HF with preserved EF in the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) study, a trial with approximately 60% of patients being women, diabetes prevalence was similar in men (27%) and women (28%). On multivariable analysis, no significant gender differences were found for the association between diabetes and clinical events⁴⁰.

In the Chronic Heart Failure Analysis and Registry in the Tohoku District-2 (CHART-2), a prospective observational study of HF in Japan (preserved EF in 75.1% of women vs in 65.8% of men, $P < 0.001$), diabetes was less prevalent in women (31.7%) vs men (36.4%; $P = 0.002$). Overall survival was similar. Analysis of predictors for all-cause mortality between genders showed significant interaction for

diabetes although no detailed hazard ratios were reported⁴¹. These data are contrasted by a pooled analysis of prospective and observational studies from Spain. The multicentre Andalusian Heart Failure Registry (RAIC) examined 795 patients with a primary diagnosis of HF⁴². The relative prevalence of diabetes compared to men was higher in women (50.7% versus 41.2% in men, $p < 0.007$). The authors did not report gender-related differences in in-hospital mortality (5.2%) or short-term morbidity (19.2%), and the relative importance of diabetes to these outcomes was not presented.

In the MAGGIC database, diabetes was found in 25.4% of women vs 22.8% of men; $p < 0.001$)²⁴. The survival benefit in women was attenuated with comorbid diabetes: the hazard ratio (95% CI) of death for men vs. women without diabetes was 1.37 (1.30-1.45), but in the presence of diabetes only 1.11 (1.03-1.20); $P < 0.0001$ for interaction)²⁴.

As with most other comorbidities in HF, diabetes is more frequently reported in registries compared to prospective randomized trials. There are important differences in epidemiology related to clinical HF status, with diabetes being more prevalent in hospitalized patients than outpatients³⁵. The current HF literature does not support a consistent gender differences with regards to comorbid diabetes. Given the generally adverse association between diabetes and clinical outcomes, gender-differences in its prevalence are likely of clinical relevance. Some reports have demonstrated that concomitant DM attenuates the female gender benefit in outcomes compared to men. Thus, the negative impact of diabetes on prognosis might be enhanced in women, highlighting an urgent need for gender-specific management strategies and for prospective gender-stratified analysis in future studies in HF.

Comment [AC6]: eliminate

Comment [AC7]: eliminate

Chronic kidney disease

Chronic kidney disease (CKD) is another adverse prognostic indicator in HF subjects^{4, 5, 7, 36, 43-47}. In previous analyses, CKD has usually been defined by past medical history, or determined from an estimated glomerular filtration rate (eGFR; for example $< 60 \text{ ml/min/1.73 m}^2$). The prevalence of concomitant CKD therefore differs widely between 14% up to 90% in various HF cohorts (e.g., acute vs. chronic; preserved vs. reduced EF) and with definition used (see Table 1)^{17, 26, 37, 48-51}. Registries and population-based surveys reported higher prevalence figures than

prospective trials which is likely due to the presence of exclusion criteria related to renal dysfunction in most HF trials.

In a retrospective cohort study of 18,322 age- and gender-matched Medicare beneficiaries with HF (59.1% women), the relative mortality risk of comorbid CKD was higher than for comorbid diabetes or colorectal cancer, and only second to lung cancer⁷.

With respect to gender, CKD has been reported more frequently in women with HF, while other authors reported male predominance or no gender-differences^{11, 23, 34, 37}. A recent epidemiological study assessing healthcare utilization and outcomes in Olmsted county, Minnesota, US reported a lower prevalence of CKD in women with both preserved EF (15% compared to men 23%) and reduced EF (14% versus 17%)²⁹.

Of note, eGFR has usually been computed using the Modification of Diet in Renal Disease equation (MDRD) formula which is based on serum creatinine, gender, age, and ethnicity, thereby potentially introducing some gender bias⁵². In the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF) the proportion of women increased with declining eGFR^{25, 53}. In contrast, in the large multicenter GWTG-HF registry (n=89,127), the prevalence for CKD was higher in men both with reduced and preserved EF, and CKD was strongly associated with increased mortality for both genders³⁷. There was no gender-difference in in-hospital mortality.

In HF with preserved EF in the I-PRESERVE study, CKD was more prevalent in women than in men (34 vs 26%, p<0.001). Despite better overall survival in female patients, the presence of an eGFR <60 ml/min/1.73 m² attenuated the survival advantage in women compared with men⁴⁰.

The National HF Registry under the Spanish Society of Internal Medicine (RICA) included 1,772 patients (836 men [47.2%] and 936 women [52.8%]) with HF and mean EF of 50%. CKD was seen more often in women than men (59.1% vs 53.0%, p<0.001) but was not associated with survival¹⁶.

CKD is highly prevalent and an important determinant of adverse outcome in HF. Registry data likely reflect the burden of comorbid CKD in HF more accurately than prospective trials from which HF patients with significant CKD traditionally have been excluded. The fact that more women with HF have hypertension, a predisposing condition for CKD, would provide a plausible explanation for female

predominance in the prevalence of CKD. Yet, comorbid CKD in HF does not seem to exhibit a consistent gender distribution pattern, rather, its prevalence varies according to HF phenotype and clinical status. Even more important, differences in study type, methodology, investigated cohorts and employed definitions for CKD likely account for most inconsistencies. Based on the negative prognostic association of comorbid CKD in HF and the finding by some authors of gender-specific differences in its prevalence, gender-specific evaluation of CKD comorbid to HF should be the subject of prospective studies. With CKD and worsening renal function also frequently being the cause of discontinuation of medical therapies for HF, future studies should assess whether CKD requires tailored, gender-specific management in order to optimize outcomes in women and men with HF.

Anemia and iron deficiency

Anemia and iron deficiency are common in HF and are associated with worse symptoms and outcomes in HF patients⁵⁴⁻⁵⁷. Commonly anemia has been defined as hemoglobin levels of <12 g/dl (7.5 mmol/l) in women and <13 g/dl (<8.1 mmol/l) in men³⁶. Dilutional anemia can occur in decompensated congestive HF and together with non-uniform cut-off definitions for anemia, may explain some discrepancies between HF cohorts. The reported prevalence of anemia in HF according to the above criteria ranges from 20-40%^{27, 57-61}. In many HF cohorts, lower hemoglobin levels have been associated with higher morbidity and mortality^{4, 37, 58-60, 62}.

Anemia seems to be more frequent in women with HF compared with men⁶³⁻⁶⁵. In the Coordinating study evaluating Outcomes of Advising and Counseling in Heart failure (COACH) biomarker analysis (n=567; mean age 71 years; 38% women), anemia was more than twice as common in women (56% vs men 26%, p<0.001).

It is important to note that anemia in heart failure is closely related to renal dysfunction, with complex and interacting pathophysiological mechanisms (cardio-renal-anemia syndrome)⁶⁶. This notion is supported by data from the Norwegian HF Registry of outpatients with advanced HF in which baseline anemia was predictive of all-cause mortality but not in the subset of patients with renal failure or advanced HF functional class⁶⁷.

The prevalence of iron deficiency in HF is at least twice that of clinically overt anemia^{55, 68}. Iron plays a key role in erythropoiesis, and normal iron metabolism is

crucial for normal function of cardiac cells⁶⁹. Iron deficiency is associated with worse outcomes in HF⁷⁰. In a prospective observational study of 546 predominantly male HF patients, female gender was an independent predictor of iron deficiency⁶⁹.

Anemia is associated with older age, higher mortality both in-hospital and long-term, and with reduced quality of life in patients with HF. Several reports suggest a marked female predominance in the prevalence of anemia and iron deficiency in HF. Apart from gender-specific epidemiological data, little is known on putative gender differences in the pathophysiology, clinical course and response to therapy of anemia and iron deficiency in HF. Ongoing studies evaluating the role of iron repletion strategies in anemia or iron deficiency comorbid to HF will provide further insights into putative gender-specific differences of these highly prevalent conditions and clarify a possible need for targeted therapies according to gender.

Frailty and arthritis

Frailty is often circumscribed as the presence of general muscle weakness, fatigue, limited mobility, unintentional weight loss and reduced physical reserve⁷¹⁻⁷⁴. Frailty increases with age and progressive HF symptoms, and predicts death and morbidity. Given the vague definition and inability to distinguish physiologic frailty of aging from that of HF and comorbid diseases, the prevalence estimates are wide and range between 10% in HF outpatients and up to 74% in hospitalized HF patients⁷⁴⁻⁷⁶. No robust data exist on the gender distribution of frailty in HF.

Osteoarthritis and rheumatoid arthritis are common in HF, especially in the elderly, and may share pathogenetic links with HF^{3, 5, 77-82}. In particular, pro-inflammatory mechanisms have been proposed. The reported prevalence of chronic knee pain and radiographic osteoarthritis according to gender in the general population has differed substantially, due to differences in study design definitions used^{79, 83, 84}.

As with osteoarthritis, the prevalence of rheumatoid arthritis in the general population, increases with age, with the presence of HF, and shows a more consistent female predominance⁸⁵⁻⁸⁷. Conversely, the prevalence of HF is higher in patients with arthritis⁸⁵. In an analysis of 34,701 patients with arthritis, gender did not confer increased risk for HF, although the incidence of HF in that cohort was too low to make definitive conclusions⁸⁸. Importantly, rheumatoid arthritis as a comorbidity to HF is associated with worse prognosis⁸⁹.

Yet, most previous HF cohort have not systematically reported comorbid arthritis. A recent study in community-dwelling HF found arthritis (of any kind) to be more prevalent in women than men, in particular in women with HF preserved EF²⁹.

Together, frailty and arthritis are very common comorbidities to HF, increase with age and carry prognostic importance. There is a striking scarcity of gender-specific data on the role these comorbidities in HF. Moreover, common arthritis therapies such as corticosteroids and non-steroidal anti-inflammatory drugs potentially exacerbate HF⁹⁰. With polypharmacy being an increasing concern in HF patients, particularly in the elderly, more gender-specific evidence is also needed for medication use for arthritis in HF.

Chronic obstructive pulmonary disease

Chronic obstructive pulmonary disease (COPD) predicts mortality in HF⁹¹. COPD has been reported to be more common in male compared with female HF patients^{33, 92}. Registries and RCTs show substantially higher rates of smoking in men, however gender differences in rates of COPD differences are less marked or absent (table)^{16, 19, 27, 34, 40, 91}. The GWTG-HF registry found smoking rates of 21% in males and 12% in females, however the prevalence of COPD was 29% in both males and females. The OPTIMIZE-HF registry had similar rates of smoking according to gender (21% males, 12 % females) with a slightly lower prevalence of COPD in females (29% vs 26%). The EuroHeart Failure Survey II (EHFS II) demonstrated higher rates of smoking in males (20%) vs females (7%) and higher rates of COPD (22% vs 15% in females).

The prevalence of COPD has decreased much more in men than in women in recent decades, a finding which has been attributed to trends in smoking patterns but is also thought to reflect women's greater susceptibility to the effects of smoking⁹³. Exact mechanisms for this are not understood, and hypotheses include that women have smaller airways leading to greater per cigarette exposure, differential metabolism of tobacco products and potentially also that a decrease in oestrogen in women smokers may exacerbate pulmonary disease⁹⁴. There also may be under-diagnosis of COPD in women due in part to a distinct clinical presentation compared with men. Women are less likely to present with phlegm and more likely to present with dyspnoea⁹³. One study surveying physicians found that they were less likely to give a diagnosis of COPD to a hypothetical female than male patient with the

same presenting symptoms⁹⁵. Diagnosing COPD in the HF population may be particularly complex given the overlap of symptoms and risk factors. This is especially true in decompensated HF as pulmonary venous congestion affects pulmonary function tests. In addition, the diagnosis of COPD is often particularly difficult in HF with preserved EF, a HF phenotype which is more common in women. A recent report assessing comorbidities in COPD showed a higher prevalence of HF in women⁹⁶.

Although COPD is a common comorbidity to HF, it is not always assessed and evaluated by pulmonary function tests. COPD negatively impacts on HF prognosis. The current literature points to male predominance in the prevalence of COPD comorbid to HF. A clinical challenge is the overlap in symptoms from HF and COPD, and further, the fact that pulmonary function tests are often unreliable in patients with decompensated HF. Drug interactions are another clinical problem: beta-blockers in HF have the potential to increase airway obstruction; in particular non-selective ones⁹⁷. Despite proven efficacy, HF patients with COPD are therefore less likely to be prescribed beta-blockers. Conversely, beta-adrenergic agents and corticosteroids for COPD may lead to tachyarrhythmia and fluid retention⁹⁸. Whether gender differences exist for the occurrence and severity of these important drug interactions should be the subject of future research.

Depression

Depression is a common comorbid condition, and often under-recognised in the HF population as symptoms can overlap with those of HF^{34, 99-105}. Depression is an independent predictor of poor outcomes in HF patients, including death and HF hospitalisation⁹⁹⁻¹⁰². It is also recognised as an independent risk factor for CAD with the same weight as smoking, hypertension and hyperlipidaemia¹⁰⁶, and depression and HF share several biological mechanisms, including neurohormonal activation and increased inflammatory markers¹⁰⁷.

As with women in the general population, women with HF have a higher burden of depression than men¹⁰⁸. A meta-analysis examining depression in HF found 16 studies in which gender differences were recorded, and demonstrated that the prevalence in women was 32.7% compared with 26.1% in men, which was 2-3 times the rate of the general population⁹⁹. Prevalence estimates varied widely in this study, from 11-67% in women, and 7-63% in men depending on how depression was

defined and which investigative tool used⁹⁹. Depressive symptoms may not be routinely assessed in HF patients, and registries and RCTs have only infrequently included details on comorbid depression (see table)^{17, 31, 34}. In the OPTIMIZE-HF registry of over 48,000 patients with ADHF, only 12.3% of women and 8.8% of men had depression. A recent study examined the gender differences in comorbid conditions in HF in Olmsted County, Minnesota, using a records linkage system which allowed virtually complete capture of health care utilisation and outcomes in residents²⁹. This study found higher rates of depression in women than men, and in both men and women, higher rates in HFpEF than HFrEF.

Overall, depression is a common condition in HF and exhibits a higher prevalence in women than men in most studies. Depression is a predictor of poor outcome in HF; moreover, depression severely and directly affects physical, mental and emotional wellbeing. In HF subjects, depression could potentially increase non-adherence to medication and other aspects of HF management¹⁰⁹. In light of the gender disparity in prevalence, comorbid depression overall may exert greater detrimental effects in women with HF than men. Therefore, the lack of systematic gender-specific assessment of depression and the paucity of published gender-specific analyses is striking and calls for dedicated assessment in future work.

Other non-cardiac comorbidities

Thyroid disease is common in HF, and both abnormally low and abnormally high thyroid function may increase HF event rates¹¹⁰⁻¹¹³. Thyroid hormone has fundamental effects on CV homeostasis^{114, 115}. The reported prevalence of abnormal thyroid function in women is at least twice that of men with HF. In women, abnormal thyroid function was reported at around 20% and 11% in OPTIMIZE-HF and EHFS II respectively, contrary to less than 10% in men in both studies (table 1)^{17, 19, 32}. Different definitions of comorbid thyroid disease may explain differences in the overall prevalence between studies.

Peripheral artery disease has been shown to predict adverse outcomes in acute myocardial infarction complicated with HF, reduced EF or both¹¹⁶. In HF, peripheral artery disease is another highly prevalent comorbidity, and exhibits male preponderance which may be due to the markedly higher percentage of male smokers within the same studies (table 1)^{16, 17, 19, 27, 34}.

The literature on gender differences of liver disease, obesity, hyperlipidemia, cognitive impairment, malignancies, mental disorders and others comorbid to HF is limited and these comorbidities are not further discussed here.

Summary and conclusion

Despite some reported gender-differences in the prevalence of non-cardiovascular comorbidities in HF, our understanding of non-cardiovascular comorbidities in HF remains incomplete. Women with HF are older and more likely than men to have comorbid hypertension, diabetes, renal failure, obesity, depression and more severe symptoms, but appear to have better overall survival. Men with HF are more often smokers and tend to have more ischemic heart disease, COPD and HF with reduced EF compared with women.

In HF clinical trials, women have traditionally been underrepresented, and interpretation of comorbidities is frequently obscured by non-uniform definitions, lack of pre-specified gender-stratification, and lack of long-term follow-up. Registries and administrative data from healthcare providers generally report higher prevalence values for comorbidities, and contrast with prospective randomized studies in the gender-specific distribution of comorbidities and their association with outcome.

There is uncertainty as to whether gender-differences exist in adherence to guideline-directed pharmacological treatment of HF as well as that of comorbidities, and whether such differences are of prognostic relevance.

Temporal changes in epidemiology suggest an increasing incidence of HFpEF compared to HFrEF, higher comorbidity burden and female predominance with the aging of HF cohorts^{4, 10, 29, 117}.

Combined efforts from regulators, trialists, health authorities and registry administrators are required to adequately fill our knowledge gap on gender-specific differences in epidemiology, pathogenesis, therapeutic management and prognostic significance of comorbidities in HF. There is an unmet need and a great opportunity for clinicians to assess whether gender-related differences in comorbidities of HF require specific management strategies.

Conflicts of interest

Robert Mentz receives research support from the NIH, Amgen, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Gilead, Novartis, Otsuka, and ResMed; honoraria from HeartWare, Janssen, Luitpold Pharmaceuticals, Novartis, ResMed, and Thoratec; and has served on an advisory board for Luitpold Pharmaceuticals, Inc.

Thomas von Lueder has received research support from the South-Eastern Norwegian Health Authority, honoraria from Novartis and has served on advisory boards for Vifor and Novartis.

Ingrid Hopper, Dipak Kotecha, and Ken Lee Chin report no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Table 1. Comorbidities and demographics at baseline according to gender in important HF studies

Comment [KHHSSU8]: Please complete and submit the separate disclosure form .pdf for each author

Formatted: Font: Bold

Comment [KHHSSU9]: Please confirm

Comment [KHHSSU10]: Due to size of Table, it may be easier to convert and relabel as a figure

References

*of importance

*of major importance

(Bullet important references published in the past 3 years and provide 1 sentence annotations to explain their importance)

1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Judd SE, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Mackey RH, Magid DJ, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER, 3rd, Moy CS, Mussolino ME, Neumar RW, Nichol G, Pandey DK, Paynter NP, Reeves MJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Wong ND, Woo D, Turner MB. Heart disease and stroke statistics--2014 update: a report from the American Heart Association. *Circulation* 2014;129(3):e28-e292.
2. Ahluwalia SC, Gross CP, Chaudhry SI, Leo-Summers L, Van Ness PH, Fried TR. Change in comorbidity prevalence with advancing age among persons with heart failure. *J Gen Intern Med* 2011;26(10):1145-51.
3. Page RL, 2nd, Lindenfeld J. The comorbidity conundrum: a focus on the role of noncardiovascular chronic conditions in the heart failure patient. *Curr Cardiol Rep* 2012;14(3):276-84.
4. Mentz RJ, Kelly JP, von Lueder TG, Voors AA, Lam CS, Cowie MR, Kjeldsen K, Jankowska EA, Atar D, Butler J, Fiuzat M, Zannad F, Pitt B, O'Connor CM. Noncardiac Comorbidities in Heart Failure With Reduced Versus Preserved Ejection Fraction. *J Am Coll Cardiol* 2014;64(21):2281-2293.
5. Krum H, Gilbert RE. Demographics and concomitant disorders in heart failure. *Lancet* 2003;362(9378):147-158.
6. Heidenreich PA, Albert NM, Allen LA, Bluemke DA, Butler J, Fonarow GC, Ikonomidis JS, Khavjou O, Konstam MA, Maddox TM, Nichol G, Pham M, Pina IL, Trogdon JG. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. *Circ Heart Fail* 2013;6(3):606-19.
7. Ahluwalia SC, Gross CP, Chaudhry SI, Ning YM, Leo-Summers L, Van Ness PH, Fried TR. Impact of comorbidity on mortality among older persons with advanced heart failure. *J Gen Intern Med* 2012;27(5):513-9.
8. Paulus WJ, Tschope C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. *J Am Coll Cardiol* 2013;62(4):263-71.

9. Wong CM, Hawkins NM, Petrie MC, Jhund PS, Gardner RS, Ariti CA, Poppe KK, Earle N, Whalley GA, Squire IB, Doughty RN, McMurray JJ. Heart failure in younger patients: the Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). *Eur Heart J* 2014;35(39):2714-21.
10. Gerber Y, Weston SA, Redfield MM, Chamberlain AM, Manemann SM, Jiang R, Killian JM, Roger VL. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. *JAMA Intern Med* 2015;175(6):996-1004.
11. Klempfner R, Koifman E, Goldenberg I, Hamdan A, Tofler GH, Kopel E. The Israel Nationwide Heart Failure Survey: Sex differences in early and late mortality for hospitalized heart failure patients. *J Card Fail* 2014;20(3):193-8.
12. Brandsaeter B, Atar D, Agewall S. Gender differences among Norwegian patients with heart failure. *Int J Cardiol* 2011;146(3):354-8.
13. Adams KF, Jr., Dunlap SH, Sueta CA, Clarke SW, Patterson JH, Blauwet MB, Jensen LR, Tomasko L, Koch G. Relation between gender, etiology and survival in patients with symptomatic heart failure. *J Am Coll Cardiol* 1996;28(7):1781-8.
14. Alla F, Al-Hindi AY, Lee CR, Schwartz TA, Patterson JH, Adams KF, Jr. Relation of sex to morbidity and mortality in patients with heart failure and reduced or preserved left ventricular ejection fraction. *Am Heart J* 2007;153(6):1074-80.
15. Tasevska-Dinevska G, Kennedy LM, Nilsson PM, Willenheimer R. Gender aspects on heart failure incidence and mortality in a middle-aged, urban, community-based population sample: the Malmo preventive project. *Eur J Epidemiol* 2009;24(5):249-57.
16. Conde-Martel A, Arkuch ME, Formiga F, Manzano-Espinosa L, Aramburu-Bodas O, Gonzalez-Franco A, Davila-Ramos MF, Suarez-Pedreira I, Herrero-Domingo A, Montero-Perez-Barquero M. Gender related differences in clinical profile and outcome of patients with heart failure. Results of the RICA Registry. *Rev Clin Esp* 2015.
17. Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, O'Connor CM, Sun JL, Yancy C, Young JB. Age- and gender-related differences in quality of care and outcomes of patients hospitalized with heart failure (from OPTIMIZE-HF). *Am J Cardiol* 2009;104(1):107-15.
18. Ghali JK, Krause-Steinrauf HJ, Adams KF, Khan SS, Rosenberg YD, Yancy CW, Young JB, Goldman S, Peberdy MA, Lindenfeld J. Gender differences in advanced heart failure: insights from the BEST study. *J Am Coll Cardiol* 2003;42(12):2128-34.
19. Nieminen MS, Harjola VP, Hochadel M, Drexler H, Komajda M, Brutsaert D, Dickstein K, Ponikowski P, Tavazzi L, Follath F, Lopez-Sendon JL. Gender related differences in patients presenting with acute heart failure. Results from EuroHeart Failure Survey II. *Eur.J.Heart Fail.* 2008;10(2):140-148.

20. Cui X, Kaspar M, Zhu H, Stork S, Ertl G, Zhou J, Ge J, Angermann CE. Clinical characteristics, treatment and survival in patients with systolic heart failure--comparative assessment of a Chinese and a German cohort. *Int J Cardiol* 2014;176(3):1388-90.
21. Adams KF, Jr., Sueta CA, Gheorghiade M, O'Connor CM, Schwartz TA, Koch GG, Uretsky B, Swedberg K, McKenna W, Soler-Soler J, Califf RM. Gender differences in survival in advanced heart failure. Insights from the FIRST study. *Circulation* 1999;99(14):1816-21.
22. O'Meara E, Clayton T, McEntegart MB, McMurray JJ, Pina IL, Granger CB, Ostergren J, Michelson EL, Solomon SD, Pocock S, Yusuf S, Swedberg K, Pfeffer MA. Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. *Circulation* 2007;115(24):3111-20.
23. Shah AN, Mentz RJ, Gheorghiade M, Kwasny MJ, Fought AJ, Zannad F, Swedberg K, Maggioni AP, Konstam MA. Gender does not affect postdischarge outcomes in patients hospitalized for worsening heart failure with reduced ejection fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan [EVEREST] Trial). *Am J Cardiol* 2012;110(12):1803-8.
24. Martinez-Selles M, Doughty RN, Poppe K, Whalley GA, Earle N, Tribouillois C, McMurray JJ, Swedberg K, Kober L, Berry C, Squire I. Gender and survival in patients with heart failure: interactions with diabetes and aetiology. Results from the MAGGIC individual patient meta-analysis. *Eur J Heart Fail* 2012;14(5):473-9.
25. Heywood JT, Fonarow GC, Yancy CW, Albert NM, Curtis AB, Stough WG, Gheorghiade M, McBride ML, Mehra MR, O'Connor CM, Reynolds D, Walsh MN. Influence of renal function on the use of guideline-recommended therapies for patients with heart failure. *Am J Cardiol* 2010;105(8):1140-6.
26. Yancy CW, Lopatin M, Stevenson LW, De Marco T, Fonarow GC. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. *J Am Coll Cardiol* 2006;47(1):76-84.
27. Klein L, Grau-Sepulveda MV, Bonow RO, Hernandez AF, Williams MV, Bhatt DL, Fonarow GC. Quality of care and outcomes in women hospitalized for heart failure. *Circ Heart Fail* 2011;4(5):589-98.
28. von Lueder TG, Atar D. Comorbidities and polypharmacy. *Heart Fail Clin* 2014;10(2):367-72.
29. Chamberlain AM, St Sauver JL, Gerber Y, Manemann SM, Boyd CM, Dunlay SM, Rocca WA, Finney Rutten LJ, Jiang R, Weston SA, Roger VL. Multimorbidity in heart failure: a community perspective. *Am J Med* 2015;128(1):38-45.

30. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. *Eur Heart J* 2012;33(14):1787-847.
31. Cheng RK, Cox M, Neely ML, Heidenreich PA, Bhatt DL, Eapen ZJ, Hernandez AF, Butler J, Yancy CW, Fonarow GC. Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population. *Am Heart J* 2014;168(5):721-30.
32. Galvao M, Kalman J, DeMarco T, Fonarow GC, Galvin C, Ghali JK, Moskowitz RM. Gender differences in in-hospital management and outcomes in patients with decompensated heart failure: analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). *J Card Fail* 2006;12(2):100-7.
33. Gustafsson I, Brendorp B, Seibaek M, Burchardt H, Hildebrandt P, Kober L, Torp-Pedersen C. Influence of diabetes and diabetes-gender interaction on the risk of death in patients hospitalized with congestive heart failure. *J Am Coll Cardiol* 2004;43(5):771-7.
34. Meyer S, van der Meer P, Massie BM, O'Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G, Davison BA, Cleland JG, Givertz MM, Bloomfield DM, Fiuzat M, Dittrich HC, Hillege HL, Voors AA. Sex-specific acute heart failure phenotypes and outcomes from PROTECT. *Eur J Heart Fail* 2013;15(12):1374-81.
35. Dei Cas A, Khan SS, Butler J, Mentz RJ, Bonow RO, Avogaro A, Tschoepe D, Doehner W, Greene SJ, Senni M, Gheorghiade M, Fonarow GC. Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure. *JACC Heart Fail* 2015;3(2):136-45.
36. Ather S, Chan W, Bozkurt B, Aguilar D, Ramasubbu K, Zachariah AA, Wehrens XH, Deswal A. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. *J Am Coll Cardiol* 2012;59(11):998-1005.
37. Hsich EM, Grau-Sepulveda MV, Hernandez AF, Peterson ED, Schwamm LH, Bhatt DL, Fonarow GC. Sex differences in in-hospital mortality in acute decompensated heart failure with reduced and preserved ejection fraction. *Am Heart J* 2012;163(3):430-7, 437 e1-3.
38. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. *Am J Cardiol* 1974;34(1):29-34.

39. Simon T, Mary-Krause M, Funck-Brentano C, Jaillon P. Sex differences in the prognosis of congestive heart failure: results from the Cardiac Insufficiency Bisoprolol Study (CIBIS II). *Circulation* 2001;103(3):375-80.
40. Lam CS, Carson PE, Anand IS, Rector TS, Kuskowski M, Komajda M, McKelvie RS, McMurray JJ, Zile MR, Massie BM, Kitzman DW. Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. *Circ Heart Fail* 2012;5(5):571-8.
41. Sakata Y, Miyata S, Nochioka K, Miura M, Takada T, Tadaki S, Takahashi J, Shimokawa H. Gender differences in clinical characteristics, treatment and long-term outcome in patients with stage C/D heart failure in Japan. Report from the CHART-2 study. *Circ J* 2014;78(2):428-35.
42. Jimenez-Navarro MF, Munoz Garcia AJ, Garcia-Pinilla JM, Gomez Hernandez G, Gomez-Doblas JJ, de Teresa Galvan E. [Trends of hospitalizations for chronic heart failure in Andalusia in the last decade]. *Rev Clin Esp* 2006;206(10):474-6.
43. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. *J Am Coll Cardiol* 2008;52(19):1527-39.
44. Go AS, Yang J, Ackerson LM, Lepper K, Robbins S, Massie BM, Shlipak MG. Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study. *Circulation* 2006;113(23):2713-23.
45. Krum H, Iyngkaran P, Lekawanvijit S. Pharmacologic management of the cardiorenal syndrome in heart failure. *Curr.Heart Fail.Rep.* 2009;6(2):105-111.
46. Mentz RJ, Lewis EF. Epidemiology of cardiorenal syndrome. *Heart Fail Clin* 2010;6(3):333-46.
47. Smith DH, Thorp ML, Gurwitz JH, McManus DD, Goldberg RJ, Allen LA, Hsu G, Sung SH, Magid DJ, Go AS. Chronic kidney disease and outcomes in heart failure with preserved versus reduced ejection fraction: the Cardiovascular Research Network PRESERVE Study. *Circ Cardiovasc Qual Outcomes* 2013;6(3):333-42.
48. Waldum B, Westheim AS, Sandvik L, Flonaes B, Grundtvig M, Gullestad L, Hole T, Os I. Renal function in outpatients with chronic heart failure. *J Card Fail* 2010;16(5):374-80.
49. Kotecha D, Holmes J, Krum H, Altman DG, Manzano L, Cleland JG, Lip GY, Coats AJ, Andersson B, Kirchhof P, von Lueder TG, Wedel H, Rosano G, Shibata MC, Rigby A, Flather MD. Efficacy of beta blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. *Lancet* 2014;384(9961):2235-43.

50. Cleland JG, Carubelli V, Castiello T, Yassin A, Pellicori P, Antony R. Renal dysfunction in acute and chronic heart failure: prevalence, incidence and prognosis. *Heart Fail Rev* 2012;17(2):133-49.
51. Heywood JT, Fonarow GC, Costanzo MR, Mathur VS, Wigneswaran JR, Wynne J. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. *J Card Fail* 2007;13(6):422-30.
52. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. *Ann Intern Med* 1999;130(6):461-70.
53. Yancy CW, Fonarow GC, Albert NM, Curtis AB, Stough WG, Gheorghide M, Heywood JT, McBride ML, Mehra MR, O'Connor CM, Reynolds D, Walsh MN. Influence of patient age and sex on delivery of guideline-recommended heart failure care in the outpatient cardiology practice setting: findings from IMPROVE HF. *Am Heart J* 2009;157(4):754-62 e2.
54. Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Borenstein J. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. *J Am Coll Cardiol* 2002;39(11):1780-6.
55. van Veldhuisen DJ, Anker SD, Ponikowski P, Macdougall IC. Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches. *Nat Rev Cardiol* 2011;8(9):485-93.
56. Ezekowitz JA, McAlister FA, Armstrong PW. The interaction among sex, hemoglobin and outcomes in a specialty heart failure clinic. *Can J Cardiol*. 2005;21(2):165-171.
57. Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. *Circulation* 2003;107(2):223-225.
58. Tang YD, Katz SD. The prevalence of anemia in chronic heart failure and its impact on the clinical outcomes. *Heart Fail Rev* 2008;13(4):387-92.
59. Tang YD, Katz SD. Anemia in chronic heart failure: prevalence, etiology, clinical correlates, and treatment options. *Circulation* 2006;113(20):2454-61.
60. Groenveld HF, Januzzi JL, Damman K, van Wijngaarden J, Hillege HL, van Veldhuisen DJ, van der Meer P. Anemia and mortality in heart failure patients a systematic review and meta-analysis. *J Am Coll Cardiol* 2008;52(10):818-27.

61. O'Meara E, Clayton T, McEntegart MB, McMurray JJ, Lang CC, Roger SD, Young JB, Solomon SD, Granger CB, Ostergren J, Olofsson B, Michelson EL, Pocock S, Yusuf S, Swedberg K, Pfeffer MA. Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. *Circulation* 2006;113(7):986-94.
62. Young JB, Abraham WT, Albert NM, Gattis Stough W, Gheorghiade M, Greenberg BH, O'Connor CM, She L, Sun JL, Yancy CW, Fonarow GC. Relation of low hemoglobin and anemia to morbidity and mortality in patients hospitalized with heart failure (insight from the OPTIMIZE-HF registry). *Am J Cardiol* 2008;101(2):223-30.
63. Le Jemtel TH, Arain S. Mediators of anemia in chronic heart failure. *Heart Fail Clin* 2010;6(3):289-93.
64. Rangel I, Goncalves A, de Sousa C, Leite S, Campelo M, Martins E, Amorim S, Moura B, Silva Cardoso J, Maciel MJ. Iron deficiency status irrespective of anemia: a predictor of unfavorable outcome in chronic heart failure patients. *Cardiology* 2014;128(4):320-6.
65. Cohen-Solal A, Damy T, Terbah M, Kerebel S, Baguet JP, Hanon O, Zannad F, Laperche T, Leclercq C, Concas V, Duville L, Darne B, Anker S, Mebazaa A. High prevalence of iron deficiency in patients with acute decompensated heart failure. *Eur J Heart Fail* 2014;16(9):984-91.
66. Kotecha D, Ngo K, Walters JA, Manzano L, Palazzuoli A, Flather MD. Erythropoietin as a treatment of anemia in heart failure: systematic review of randomized trials. *Am Heart J* 2011;161(5):822-831 e2.
67. Waldum B, Westheim AS, Sandvik L, Flonaes B, Grundtvig M, Gullestad L, Hole T, Os I. Baseline anemia is not a predictor of all-cause mortality in outpatients with advanced heart failure or severe renal dysfunction. Results from the Norwegian Heart Failure Registry. *J Am Coll Cardiol* 2012;59(4):371-8.
68. Nanas JN, Matsouka C, Karageorgopoulos D, Leonti A, Tsolakis E, Drakos SG, Tsagalou EP, Maroulidis GD, Alexopoulos GP, Kanakakis JE, Anastasiou-Nana MI. Etiology of anemia in patients with advanced heart failure. *J Am Coll Cardiol* 2006;48(12):2485-9.
69. Jankowska EA, Rozentryt P, Witkowska A, Nowak J, Hartmann O, Ponikowska B, Borodulin-Nadzieja L, Banasiak W, Polonski L, Filippatos G, McMurray JJ, Anker SD, Ponikowski P. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. *Eur Heart J* 2010;31(15):1872-80.
70. Okonko DO, Mandal AK, Missouriis CG, Poole-Wilson PA. Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation to anemia, exercise capacity, and survival. *J Am Coll Cardiol* 2011;58(12):1241-51.

71. Afilalo J. Frailty in Patients with Cardiovascular Disease: Why, When, and How to Measure. *Curr Cardiovasc Risk Rep* 2011;5(5):467-472.
72. McNallan SM, Singh M, Chamberlain AM, Kane RL, Dunlay SM, Redfield MM, Weston SA, Roger VL. Frailty and healthcare utilization among patients with heart failure in the community. *JACC Heart Fail* 2013;1(2):135-41.
73. Afilalo J, Karunanathan S, Eisenberg MJ, Alexander KP, Bergman H. Role of frailty in patients with cardiovascular disease. *Am J Cardiol* 2009;103(11):1616-21.
74. Goldwater DS, Pinney SP. Frailty in Advanced Heart Failure: A Consequence of Aging or a Separate Entity? *Clin Med Insights Cardiol* 2015;9(Suppl 2):39-46.
75. McNallan SM, Chamberlain AM, Gerber Y, Singh M, Kane RL, Weston SA, Dunlay SM, Jiang R, Roger VL. Measuring frailty in heart failure: a community perspective. *Am Heart J* 2013;166(4):768-74.
76. Afilalo J, Alexander KP, Mack MJ, Maurer MS, Green P, Allen LA, Popma JJ, Ferrucci L, Forman DE. Frailty assessment in the cardiovascular care of older adults. *J Am Coll Cardiol* 2014;63(8):747-62.
77. Ong KL, Wu BJ, Cheung BM, Barter PJ, Rye KA. Arthritis: its prevalence, risk factors, and association with cardiovascular diseases in the United States, 1999 to 2008. *Ann Epidemiol* 2013;23(2):80-6.
78. Rahman MM, Kopec JA, Anis AH, Cibere J, Goldsmith CH. Risk of cardiovascular disease in patients with osteoarthritis: a prospective longitudinal study. *Arthritis Care Res (Hoboken)* 2013;65(12):1951-8.
79. Thomas E, Peat G, Harris L, Wilkie R, Croft PR. The prevalence of pain and pain interference in a general population of older adults: cross-sectional findings from the North Staffordshire Osteoarthritis Project (NorStOP). *Pain* 2004;110(1-2):361-8.
80. Rahman MM, Kopec JA, Cibere J, Goldsmith CH, Anis AH. The relationship between osteoarthritis and cardiovascular disease in a population health survey: a cross-sectional study. *BMJ Open* 2013;3(5).
81. Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, Liang MH, Kremers HM, Mayes MD, Merkel PA, Pillemer SR, Reveille JD, Stone JH. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. *Arthritis Rheum* 2008;58(1):15-25.

82. Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, Gabriel S, Hirsch R, Hochberg MC, Hunder GG, Jordan JM, Katz JN, Kremers HM, Wolfe F. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. *Arthritis Rheum* 2008;58(1):26-35.
83. Lacey RJ, Thomas E, Duncan RC, Peat G. Gender difference in symptomatic radiographic knee osteoarthritis in the Knee Clinical Assessment--CAS(K): a prospective study in the general population. *BMC Musculoskelet Disord* 2008;9:82.
84. Dillon CF, Rasch EK, Gu Q, Hirsch R. Prevalence of knee osteoarthritis in the United States: arthritis data from the Third National Health and Nutrition Examination Survey 1991-94. *J Rheumatol* 2006;33(11):2271-9.
85. Han C, Robinson DW, Jr., Hackett MV, Paramore LC, Fraeman KH, Bala MV. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. *J Rheumatol* 2006;33(11):2167-72.
86. Zhu Y, Pandya BJ, Choi HK. Comorbidities of Gout and Hyperuricemia in the US General Population: NHANES 2007-2008. *Am J Med* 2012;125(7):679-687 e1.
87. Doherty M. New insights into the epidemiology of gout. *Rheumatology (Oxford)* 2009;48 Suppl 2:ii2-ii8.
88. Krum H, Curtis SP, Kaur A, Wang H, Smugar SS, Weir MR, Laine L, Brater DC, Cannon CP. Baseline factors associated with congestive heart failure in patients receiving etoricoxib or diclofenac: multivariate analysis of the MEDAL program. *Eur.J.Heart Fail.* 2009;11(6):542-550.
89. Davis JM, III, Roger VL, Crowson CS, Kremers HM, Therneau TM, Gabriel SE. The presentation and outcome of heart failure in patients with rheumatoid arthritis differs from that in the general population. *Arthritis Rheum.* 2008;58(9):2603-2611.
90. Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. *Arch.Intern.Med.* 2000;160(6):777-784.
91. De Blois J, Simard S, Atar D, Agewall S. COPD predicts mortality in HF: the Norwegian Heart Failure Registry. *J Card Fail* 2010;16(3):225-9.
92. Vaccarino V, Chen YT, Wang Y, Radford MJ, Krumholz HM. Sex differences in the clinical care and outcomes of congestive heart failure in the elderly. *Am Heart J* 1999;138(5 Pt 1):835-42.
93. Aryal S, Diaz-Guzman E, Mannino DM. COPD and gender differences: an update. *Transl Res* 2013;162(4):208-18.

94. Bhatt SP, Dransfield MT. Chronic obstructive pulmonary disease and cardiovascular disease. *Transl Res* 2013;162(4):237-51.
95. Chapman KR, Tashkin DP, Pye DJ. Gender bias in the diagnosis of COPD. *Chest* 2001;119(6):1691-5.
96. Dal Negro RW, Bonadiman L, Turco P. Prevalence of different comorbidities in COPD patients by gender and GOLD stage. *Multidiscip Respir Med* 2015;10(1):24.
97. Jabbour A, Macdonald PS, Keogh AM, Kotlyar E, Mellemkjaer S, Coleman CF, Elsik M, Krum H, Hayward CS. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. *J.Am.Coll.Cardiol.* 2010;55(17):1780-1787.
98. Mentz RJ, Fiuzat M, Kraft M, Lindenfeld J, O'Connor CM. Bronchodilators in heart failure patients with COPD: is it time for a clinical trial? *J Card Fail* 2012;18(5):413-22.
99. Rutledge T, Reis VA, Linke SE, Greenberg BH, Mills PJ. Depression in heart failure a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes. *J Am Coll Cardiol* 2006;48(8):1527-37.
100. Angermann CE, Gelbrich G, Stork S, Schowalter M, Deckert J, Ertl G, Faller H. Somatic correlates of comorbid major depression in patients with systolic heart failure. *Int J Cardiol* 2011;147(1):66-73.
101. Faller H, Stork S, Schowalter M, Steinbuchel T, Wollner V, Ertl G, Angermann CE. Depression and survival in chronic heart failure: does gender play a role? *Eur J Heart Fail* 2007;9(10):1018-23.
102. Krum H, Iyngkaran P. The black dog and the weak heart: comorbid depression in the patient with heart failure. *J.Card Fail.* 2008;14(6):465-466.
103. Lesman-Leegte I, Jaarsma T, Sanderman R, Hillege HL, van Veldhuisen DJ. Determinants of depressive symptoms in hospitalised men and women with heart failure. *Eur J Cardiovasc Nurs* 2008;7(2):121-6.
104. McGann PE. Comorbidity in heart failure in the elderly. *Clin Geriatr Med* 2000;16(3):631-48.
105. Wallenborn J, Angermann CE. Comorbid depression in heart failure. *Herz* 2013;38(6):587-96.
106. Frasure-Smith N, Lesperance F, Talajic M. Depression following myocardial infarction. Impact on 6-month survival. *JAMA* 1993;270(15):1819-25.

107. Moudgil R, Haddad H. Depression in heart failure. *Curr Opin Cardiol* 2013;28(2):249-58.
108. Kornstein SG. Gender differences in depression: implications for treatment. *J Clin Psychiatry* 1997;58 Suppl 15:12-8.
109. Farrell K, Shen BJ, Mallon S, Penedo FJ, Antoni MH. Utility of the Millon Behavioral Medicine Diagnostic to predict medication adherence in patients diagnosed with heart failure. *J Clin Psychol Med Settings* 2011;18(1):1-12.
110. Hamilton MA. Prevalence and clinical implications of abnormal thyroid hormone metabolism in advanced heart failure. *Ann Thorac Surg* 1993;56(1 Suppl):S48-52; discussion S52-3.
111. Gencer B, Collet TH, Virgini V, Bauer DC, Gussekloo J, Cappola AR, Nanchen D, den Elzen WP, Balmer P, Luben RN, Iacoviello M, Triggiani V, Cornuz J, Newman AB, Khaw KT, Jukema JW, Westendorp RG, Vittinghoff E, Aujesky D, Rodondi N. Subclinical thyroid dysfunction and the risk of heart failure events: an individual participant data analysis from 6 prospective cohorts. *Circulation* 2012;126(9):1040-9.
112. Goldman S, Thomson S, McCarren M. Clinical implications of abnormal thyroid function in heart failure. *JACC Heart Fail* 2013;1(1):56-7.
113. Roos A, Links TP, Wolffenbuttel BH. Subclinical thyroid disease and heart failure. *Eur J Heart Fail* 2014;16(2):119-21.
114. Thomas TA, Kuzman JA, Anderson BE, Andersen SM, Schlenker EH, Holder MS, Gerdes AM. Thyroid hormones induce unique and potentially beneficial changes in cardiac myocyte shape in hypertensive rats near heart failure. *Am J Physiol Heart Circ Physiol* 2005;288(5):H2118-22.
115. d'Amati G, di Gioia CR, Mentuccia D, Pistilli D, Proietti-Pannunzi L, Miraldi F, Gallo P, Celi FS. Increased expression of thyroid hormone receptor isoforms in end-stage human congestive heart failure. *J Clin Endocrinol Metab* 2001;86(5):2080-4.
116. Inglis SC, Bechuk J, Al-Suhaim SA, Case J, Pfeffer MA, Solomon SD, Hou YR, Pitt B, Dargie HJ, Ford I, Kjekshus J, Zannad F, Dickstein K, McMurray JJ. Peripheral artery disease and outcomes after myocardial infarction: An individual-patient meta-analysis of 28,771 patients in CAPRICORN, EPEHESUS, OPTIMAAL and VALIANT. *Int J Cardiol* 2013;168(2):1094-101.
117. Wong CY, Chaudhry SI, Desai MM, Krumholz HM. Trends in comorbidity, disability, and polypharmacy in heart failure. *Am J Med* 2011;124(2):136-43.